LAIA

In the world a woman dies woman dies every 2 min from cervical cancer, in underdeveloped countries, this cancer is the second leading cause of death among women worldwide and 8 of 10 cases are detected in advance stage.

The 3 main factors for a late diagnosis are the number of specialists that exist because they do not meet the necessary demand for these studies, the response time in cities is 1 week to 1 month, but in rural areas it is up to 6 months and that there is no access to medical information. If a second opinion is required, it is necessary to perform the study again to generate a new diagnosis.

We digitize pathological studies that currently can only be reviewed on a glass slide to be viewed under a microscope. We detect cervical cancer lesions in the digital images we obtain. The detection is through our Artificial Intelligence.We centralize the information through our web platform where you can manage the studies at each stage required. From sample collection to diagnosis and clinical record.

LAIA supports the diagnostic process of pathological studies to reduce turnaround time and make these studies available for consultation at any location. Our goal is to impact the turnaround time of these studies by supporting the laboratory and physicians with our web platform so that they can be properly followed up.

We are a technological team that seeks to provide technological solutions to the medical area. At first the objective was to create a new diagnostic system that we knew was going to take time to build, but by being in contact with the medical processes we were able to create a solution that integrates the stages that these studies require in one place and supports the current process. We do this through our web platform 

WE ARE CURRENTLY BEING USED BY AN ORGANIZATION THAT PERFORMS PAP SMEAR TESTS IN RURAL AREAS AND THEIR PROCESS IS TRADITIONAL, THE PROCESS IS DONE ON PAPER AND THE RESULTS ARE PRINTED.

We are looking for mentors who can support us in the different challenges we face, such as approaching more organizations and achieving clinical validation of LAIA because it is a technological tool that can support decision making in the medical area and is designated as a grade I medical device. This implies carrying out massive tests to reach validation by a governmental entity.